The present invention relates to a composition which has a low affinity with respect to latex gloves, comprising a hydrophobic matrix, characterized in that said hydrophobic matrix comprises: for 100 parts by weight of a mixture P of 2 styrene-saturated olefin-styrene triblock copolymers, a first which has a viscosity of between 0.01 and 1 Pa.Math.s as measured in a 5% (weight/weight) solution in toluene and a second which has a viscosity of between 0.01 and 0.5 Pa.Math.s measured in a 15% (weight/weight) solution in toluene; from 300 to 1000 parts by weight of a plasticizer H, preferably a plasticizing oil; and from 90 to 600 parts by weight of petroleum jelly V;
it also being specified that: the total amount, represented by P+H+V, of the mixture of elastomers, of plasticizer and of petroleum jelly is between 490 and 1700 parts by weight; the ratio between the total amount of the mixture of elastomers, of plasticizer and of petroleum jelly and the amount of petroleum jelly, represented by P+H+V/V, is less than 11;
and said mixture of 2 copolymers comprises at least 20% by weight of the first copolymer.

The present invention also relates to an interface dressing with reinforcement, with a support or which is self-supported, which dressing comprises such a composition.

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

Polymeric materials are disclosed herein that include a Polymer A, a Polymer B, and an oxalate ester or reaction product thereof. Polymer A contains electrophilic reactive groups, and Polymer B contains nucleophilic groups. In certain embodiments, the polymeric materials are free-flowing liquids at 100% solids that can be used, for example, as topical skin adhesives.

Disclosed are fibrin-specific nanogels. The fibrin-specific nanogels can comprise a fibrin binding moiety conjugated to a polymeric matrix (e.g., a crosslinked polyacrylamide matrix). By varying the morphology of fibrin-specific nanogels (e.g., by varying the crosslinker density and/or the three-dimensional structure of the fibrin-specific nanogels), fibrin-specific materials which mimic the biophysical characteristics of platelets can be formed. The resulting materials can be used in a variety of biomedical applications (e.g., for drug delivery, to promote wound healing, to treat thrombotic events, and to treat coagulative disorders).

Disclosed are fibrin-specific nanogels. The fibrin-specific nanogels can comprise a fibrin binding moiety conjugated to a polymeric matrix (e.g., a crosslinked polyacrylamide matrix). By varying the morphology of fibrin-specific nanogels (e.g., by varying the crosslinker density and/or the three-dimensional structure of the fibrin-specific nanogels), fibrin-specific materials which mimic the biophysical characteristics of platelets can be formed. The resulting materials can be used in a variety of biomedical applications (e.g., for drug delivery, to promote wound healing, to treat thrombotic events, and to treat coagulative disorders).

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.